- Home
- » Tags
- » Quizartinib
Top View
- Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: the Path to Least Resistance
- Tyrosine Kinase Inhibition Increases the Cell Surface Localization of FLT3-ITD and Enhances FLT3-Directed Immunotherapy of Acute Myeloid Leukemia
- LEE-DISSERTATION-2019.Pdf
- Haematologica.Org/Content/104/10/2017 Tinib Through Combined Upregulation of AXL Activity
- Quizartinib, a Selective FLT3 Inhibitor, Maintains Antileukemic Activity in Preclinical Models of RAS-Mediated Midostaurin- Resistant Acute Myeloid Leukemia Cells
- Acute Myeloid Leukemia
- FLT3 Signalling Pathways in Acute Myeloid Leukaemia
- Quizartinib for Treating Relapsed Or Refractory Acute Myeloid Leukaemia
- HOPA News Volume 10, Issue 1
- November 2018
- Outcomes with Sequential FLT3-Inhibitor-Based Therapies In
- Targeting the FMS-Like Tyrosine Kinase 3 in Acute Myeloid Leukemia
- Nuclear Factor of Activated T-Cells, NFATC1, Governs FLT3ITD-Driven Hematopoietic Stem Cell Transformation and a Poor Prognosis
- CBL Family E3 Ubiquitin Ligases Control JAK2 Ubiquitination and Stability in Hematopoietic Stem Cells and Myeloid Malignancies
- 211349Orig1s000
- Recent Advances in the Cellular and Molecular Understanding of Myelodysplastic Syndromes: Implications for New Therapeutic Approaches
- Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments
- Final Scope PDF 218 KB
- A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: a Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study Todd M
- STAT Transcription Factors in Hematopoiesis and Leukemogenesis: Opportunities for Therapeutic Intervention
- (12) United States Patent (10) Patent No.: US 9,555,031 B2 Wang Et Al
- Lambda Research Newsletter July 2018
- Ventegra Overview
- Quizartinib in Relapsed/Refractory FLT3-ITD Acute Myeloid Leukemia
- Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling While Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells
- Recent Advances and Novel Agents for FLT3 Mutated Acute Myeloid Leukemia
- Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
- 1 Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant
- SELLAS Life Sciences Group, Inc. (Exact Name of Registrant As Specified in Its Charter) ______
- 1 MEK-Dependent Negative Feedback
- Pipeline Report
- Catalytic Receptors
- Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
- Catalytic Receptors
- SUPPLEMENTARY APPENDIX Outcomes of Relapsed Or Refractory Acute Myeloid Leukemia After Front-Line Hypomethylating Agent and Venetoclax Regimens
- Understanding Your Diagnosis: Acute Myeloid Leukemia (Aml)
- The Emergence of Drug Resistance to Targeted Cancer Therapies Clinical
- Quizartinib Versus Salvage Chemotherapy in Relapsed Or Refractory FLT3-ITD Acute Myeloid Leukaemia (Quantum-R): a Multicentre, R
- Feedbacks and Adaptive Capabilities of the PI3K/Akt/Mtor Axis in Acute Myeloid Leukemia Revealed by Pathway Selective Inhibition and Phosphoproteome Analysis
- Approved Drugs • on Nov. 16, the U.S. Food and Drug Administration (FDA) Approved Adcetris® (Brentuximab Vedotin) (Seattle Ge
- NDO Home | Contact | Register for NDO Access
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Azacitidine Combined with the Selective FLT3 Kinase Inhibitor Crenolanib Disrupts Stromal Protection and Inhibits Expansion of R
- Company Overview Investor Presentation NASDAQ
- Inhibition of FLT3 in AML: a Focus on Sorafenib
- Vanflyta; INN-Quizartinib
- Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: a Retrospective Single-Center Experience
- DAIICHI-SANKYO Briefing Information, QUIZARTINIB Tablets, for the May
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia
- Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML